Non-small-cell lung cancer
C Gridelli, A Rossi, DP Carbone, J Guarize… - Nature reviews Disease …, 2015 - nature.com
Lung cancer is one of the most frequently diagnosed cancers and is the leading cause of
cancer-related death worldwide. Non-small-cell lung cancer (NSCLC), a heterogeneous …
cancer-related death worldwide. Non-small-cell lung cancer (NSCLC), a heterogeneous …
First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer
J Greenhalgh, A Boland, V Bates… - Cochrane Database …, 2021 - cochranelibrary.com
Background Epidermal growth factor receptor (EGFR) mutation positive (M+) non‐small cell
lung cancer (NSCLC) is an important subtype of lung cancer comprising 10% to 15% of non …
lung cancer (NSCLC) is an important subtype of lung cancer comprising 10% to 15% of non …
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug …
C Davis, H Naci, E Gurpinar, E Poplavska, A Pinto… - bmj, 2017 - bmj.com
Objective To determine the availability of data on overall survival and quality of life benefits
of cancer drugs approved in Europe. Design Retrospective cohort study. Setting Publicly …
of cancer drugs approved in Europe. Design Retrospective cohort study. Setting Publicly …
Systemic therapy for stage IV non–small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update
GA Masters, S Temin, CG Azzoli, G Giaccone… - Journal of Clinical …, 2015 - ascopubs.org
Purpose To provide evidence-based recommendations to update the American Society of
Clinical Oncology guideline on systemic therapy for stage IV non–small-cell lung cancer …
Clinical Oncology guideline on systemic therapy for stage IV non–small-cell lung cancer …
[HTML][HTML] Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced …
C Zhou, YL Wu, G Chen, J Feng, XQ Liu, C Wang… - Annals of …, 2015 - Elsevier
Background The OPTIMAL study was the first study to compare efficacy and tolerability of the
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
CK Lee, L Davies, YL Wu, T Mitsudomi… - JNCI: Journal of the …, 2017 - academic.oup.com
Background: We performed an individual patient data meta-analysis to examine the impact
of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) …
of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) …
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial
Background The results of FASTACT, a randomised, placebo-controlled, phase 2 study,
showed that intercalated chemotherapy and erlotinib significantly prolonged progression …
showed that intercalated chemotherapy and erlotinib significantly prolonged progression …
Patient-centered palliative care for patients with advanced lung cancer
JS Temel, LA Petrillo, JA Greer - Journal of Clinical Oncology, 2022 - ascopubs.org
The evidence base demonstrating the benefits of an early focus on palliative care for
patients with serious cancers, including advanced lung cancer, is substantial. Early …
patients with serious cancers, including advanced lung cancer, is substantial. Early …
[HTML][HTML] Oncogene-addicted non-small-cell lung cancer: treatment opportunities and future perspectives
MG Ferrara, V Di Noia, E D'Argento, E Vita, P Damiano… - Cancers, 2020 - mdpi.com
Before the introduction of tyrosine kinase inhibitors (TKIs) for a particular subgroup of
patients, despite platinum-based combination chemotherapy, the majority of patients …
patients, despite platinum-based combination chemotherapy, the majority of patients …
Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation‐Positive Non‐Small Cell Lung Cancer: A Prospective, Single‐Arm, Phase II Study
L Xiong, R Li, J Sun, Y Lou, W Zhang, H Bai… - The …, 2019 - academic.oup.com
Abstract Lessons Learned The findings of this prospective, single‐arm, phase II study
showed that neoadjuvant erlotinib was well tolerated and might improve the radical …
showed that neoadjuvant erlotinib was well tolerated and might improve the radical …